 CANTON, Mass., Jan. 14, 2021 GLOBE NEWSWIRE -- Organogenesis Holdings Inc. Nasdaq: ORGO, a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical Sports Medicine markets, today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft ASA, for the management of symptoms associated with knee osteoarthritis OA. 